Om

SciBase Holding AB is a medical technology company specializing in advanced diagnostic solutions for skin conditions. The company develops, manufactures, and commercializes Nevisense, a point-of-care platform that combines augmented intelligence and electrical impedance spectroscopy (EIS) to support clinicians in assessing skin cancer risk and skin barrier function. Nevisense is designed to improve diagnostic accuracy in routine dermatology workflows, particularly for the early detection of melanoma and other skin disorders, and is used by dermatologists and skin cancer clinics in both Europe and the United States. SciBase’s technology supports proactive skin health management by providing objective, non-invasive measurements that complement visual examination and dermoscopy. Headquartered in Stockholm, Sweden, SciBase today operates in multiple international markets, with a focus on dermatology practices where improved risk assessment and early detection can enhance clinical decision-making and patient management.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I SCIBASE HOLDING MED ENDAVU: Køb Scibase Holding ($5J30) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Scibase Holding, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.